Literature DB >> 16445653

HER-2 codon 655 polymorphism in cervical carcinogenesis.

M Ueda1, Y-C Hung, Y Terai, J Saito, O Nunobiki, S Noda, M Ueki.   

Abstract

HER-2 codon 655 polymorphism together with human papillomavirus (HPV) types were examined in a total of 279 cervical smear samples. Forty-nine patients with high-grade squamous intraepithelial lesion had higher frequency of high-risk HPV than 167 patients with low-grade squamous intraepithelial lesion and 63 controls. There was no statistical difference in the frequencies of HER-2 Ile/Ile, Ile/Val, and Val/Val genotypes between squamous intraepithelial lesions (SILs) and controls. When the Ile/Ile genotype was compared to the Ile/Val + Val/Val genotypes, there was also no statistical difference in the genotype prevalence between SILs and controls either in 91 or 188 patients with or without high-risk HPV, respectively. These results suggest that the HER-2 polymorphism at codon 655 in cervical cell samples is unlikely to be associated with HPV status and the onset of cervical cancer in a Japanese population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16445653     DOI: 10.1111/j.1525-1438.2006.00349.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  2 in total

1.  ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers.

Authors:  Paola D Vermeer; Megan Bell; Kimberly Lee; Daniel W Vermeer; Byrant G Wieking; Erhan Bilal; Gyan Bhanot; Ronny I Drapkin; Shridar Ganesan; Aloysius J Klingelhutz; Wiljan J Hendriks; John H Lee
Journal:  PLoS One       Date:  2012-01-18       Impact factor: 3.240

2.  The Effect of HER2 Single Nucleotide Polymorphisms on Cervical Cancer Susceptibility and Survival in a Chinese Population.

Authors:  Yan Gao; Xiuwu Tang; Jieqin Cao; Rong Rong; Zhengmin Yu; Yang Liu; Yan Lu; Xiaowen Liu; Lei Han; Jiting Liu; Jun Zhang; Ming Xu; Fang Liu
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.